Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial.

Summary, in English

Prediction of radiographic progression (RP) in early rheumatoid arthritis (eRA) would be very useful for optimal choice among available therapies. We evaluated a multi-biomarker disease activity (MBDA) score, based on 12 serum biomarkers as a baseline predictor for 1-year RP in eRA.

• Author: Karen Hambardzumyan; Rebecca Bolce; Saedis Saevarsdottir; Scott E Cruickshank; Eric H Sasso; David Chernoff; Kristina Forslind; Ingemar Petersson; Pierre Geborek; Ronald F van Vollenhoven
• Department/s: Clinical Sciences, Helsingborg; Orthopaedics (Lund); Rheumatology; EpiHealth: Epidemiology for Health
• Publishing year: 2015
• Language: English
• Pages: 1102-1109
• Publication/Series: Annals of the Rheumatic Diseases
• Volume: 74
• Issue: 6
• Links: http://www.ncbi.nlm.nih.gov/pubmed/24812287?dopt=Abstract; http://dx.doi.org/10.1136/annrheumdis-2013-204986
• Document type: Journal article
• Publisher: BMJ Publishing Group
• Topic: Rheumatology and Autoimmunity
• Status: Published
• ISBN/ISSN/Other: ISSN: 1468-2060